Biopharmaceutical Company “Promomed” Begins Supply of Ozempic Analogs to Uzbekistan

Tashkent, Uzbekistan (UzDaily.com) — The biopharmaceutical company Promomed has started supplying Uzbekistan with analogs of the drug Ozempic, based on semaglutide, intended for the treatment of type 2 diabetes and management of excess body weight, the company’s press service reported.

“Promomed announces its entry into the pharmaceutical market of the Republic of Uzbekistan. The strategic decision involves a phased introduction with a focus on high-tech innovative medications.

Pharmacies across the country now offer endocrinology-related drugs for the therapy of type 2 diabetes and excess weight management,” the statement reads.

The company is also collaborating with leading endocrinologists, reproductive specialists, and other experts in the country to implement an obesity management program. In partnership with the Ministry of Health, educational initiatives for doctors and patients are planned.

“We observe a well-founded interest from both the patient community and the government in the latest pharmaceutical developments,” noted Alisher Zakirov, Head of Promomed’s representative office in Uzbekistan.

As part of its long-term strategy, the company plans to expand its market presence and include in its supply portfolio modern medications for the treatment of diabetes and obesity, as well as drugs for oncology therapy.